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Abstract: The older-adult population is constantly increasing, hence aging and mechanisms 
leading to aging are a topic raising increasing interest. Hypovitaminosis D is common amongst 
old patients and has been proposed as causative of several chronic diseases. Here we review the 
role of hypovitaminosis D and vitamin D supplementation in sarcopenia and dementia, from 
bench to bedside. 
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1. Introduction  
Due to an increased life expectancy, aging and the mechanisms leading to it have become a 
pivotal issue in scientific research. Together with innocuous and physiological changes due to 
aging, there are pathological changes that increase the risk of disease, disability, or death linked to 
the development of frailty and chronic diseases, hence older adults can be divided into the fit and 
the frail. 
During aging, all systems and organs are physiologically reduced in their function. However, 
identifying the risk factors leading to “fit” or “frail” aging is fundamental in order to understand 
the physiopathological mechanisms leading to frailty and suggest preventive measures. Health 
maintenance in older age is one the most important challenges for future medicine. Hence, 
ameliorating the burden of chronic disease in the elderly is also one of the goals of future medicine. 
Among the chronic conditions that severely affect patient quality of life, diseases affecting mobility 
and cognition—namely, sarcopenia and dementia—are the most widely suffered. Both sarcopenia 
and dementia are a severe burden for older people and both diseases are hallmarks of frailty. 
Sarcopenia and its consequences (weakness, slowness, reduction of physical activity, and weight 
loss) are essential features of “physical frailty” [1]. Whereas cognitive impairment is a characteristic 
feature of “cognitive frailty”, this is a recently defined condition in which physical frailty coexists 
with cognitive impairment [2].As both sarcopenia and dementia significantly contribute to frailty, 
herein we review the impact of hypovitaminosis D on these two diseases. 
With the term “sarcopenia”, we indicate a condition characterized by both reduced muscle 
mass and muscle strength (“dynapenia”). These declines lead to an impairment in physical 
performance [3]. Due to the heterogeneity of the criteria used to diagnose sarcopenia, with different 
working groups providing their own definitions, it is difficult to compare the results of different 
studies. Table 1 summarizes the criteria used for the diagnosis of sarcopenia. 
One of the most used algorithms in clinical practice is the algorithm recently developed by the 
European Working Group on Sarcopenia in Older People (EWGSOP) [4] (Figure 1). 
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According to the EWGSOP definition, the estimated prevalence of sarcopenia is 10–40% 
amongst elderly individuals in the community [5,6], however, this prevalence rises in settings of 
care for older patients. Due to increasing life expectancy, the number of patients living with 
sarcopenia is expected to grow to more than 200 million in the next 40 years [3]. 
Table 1. Different criteria for the diagnosis of sarcopenia. 
Criterium Slowness Weakness Low Lean Mass Summary Definition 
International 
Working Group [7]  
Gait speed < 
1.0 m/s 
Not included ALM/ht2 ≤ 7.23 kg/m2 Sarcopenia: slowness and 
low lean mass 
EWGSOP [8] Gait speed ≤ 0.8 m/s 
Grip strength 
< 30 kg 
ALM/ht2 ≤ 7.23 kg/m2 
(1) Sarcopenia: low lean 
mass plus slowness or 
weakness 
(2) Severe sarcopenia: all 
three criteria 
FNIH Sarcopenia Project 
primary definition [9]  
Gait speed ≤ 
0.8 m/s 
Grip strength 
< 26 kg 
ALM/body mass index < 
0.789 
(1) Weakness and low lean 
mass 
(2) Slowness with weakness 
and low lean mass 
Baumgartner [10]  Not included Not included ALM/ht2 ≤ 7.23 kg/m2 Low lean mass 
Newman [11]  Not included Not included 
Residual of actual ALM*-
predicted ALM from 
equation 
Low lean mass 
* ALM: appendicular lean mass. 
 
Figure 1. EWGSOP clinical practice algorithm for the diagnosis of sarcopenia. 
Being sarcopenic increases sanitary costs and decreases quality of life in older patients [12,13], 
hence the correct identification of risk factors linked to sarcopenia is important to precociously 
identify these patients and to set up an early intervention. In our “aging world”, cognitive 
impairment is also constantly increasing. The World Alzheimer Report 2018 [14] states that about 50 
million people worldwide suffer from dementia and the epidemiological projection envisions that 
these numbers are expected to rise to 152 million by 2050. 
The most diffuse form of dementia is Alzheimer’s disease (AD). Other types of dementia are 
vascular dementia, mixed dementia, and Lewy body dementia. Dementia and sarcopenia are 
responsible for an enormous increase in sanitary costs; the United States spent about $818 billion for 
Nutrients 2020, 12, 628 3 of 11 
patients with dementia in 2015, and these costs have increased by more than 30% since 2010. The 
cost distribution is not homogeneous and the majority of costs burden high-income countries [15] . 
Both sarcopenia and dementia have been associated with hypovitaminosis D, which has been 
suggested as one of the causative mechanisms. Although different values have been used as 
references and the agreed threshold for the diagnosis of hypovitaminosis D is still debated, 
hypovitaminosis D is widely diffuse among older people. Guidelines from different scientific 
societies and different countries establish the threshold for hypovitaminosis D as being under 50 
nmol/L or 75 nmol/L of blood 25(OH) vitamin D (25(OH)D3) [Table 2]. 
Table 2. Different vitamin D cut-offs used in clinical practice. 
 Vitamin D 
Source Deficiency Insufficiency Sufficiency 
IOM (2010) [16]  30 nmol/L 30–50 nmol/L 75–250 nmol/L 
U.S Endocrine Society 
(2011) [17]  50 nmol/L 50–75 nmol/L 75–250 nmol/L 
SIOMMS (2016) [18]  
<25 
nmol/L 
25–50 nmol/L 50–80 nmol/L 
AME (2018) [19]    
>75 nmol/L in patients at risk of bone 
disease 
Despite these different thresholds, the majority of studies indicate that with 25(OH)D3 lower 
than 50 nmol/L, bone metabolism is impaired and there is an increased risk of fractures, falls, and 
myopathy [20,21]. Priemel and colleagues demonstrated that pathological mineralization defects of 
bone occur in patients with a serum 25(OH)D3 below 75 nmol/L [22]. In contrast with the above 
mentioned studies, two recent randomized controlled clinical trials [23,24] indicated that only 
individuals with baseline 25(OH)D3 levels lower than 30 nmol/L will benefit from vitamin D 
supplement use. 
Clinicians working on vitamin D generally agree to maintain 25(OH)D3 levels between 20 and 
125 nmol/L. These prudential levels are associated with a healthy skeleton and avoid possible toxic 
effects. Recent papers have raised caveats concerning toxic effects of high doses of vitamin D: the 
administration of a bolus of vitamin D3 higher than 50,000 UI may result in an increased risk of falls 
and fractures [25,26] . Moreover, levels of vitamin D higher than 150 nmol/L have been associated 
with increased mortality in a wide population study [27] . 
Hypovitaminosis D has been described as common to different chronic diseases linked to 
senescence, and the incidence of hypovitaminosis D increases as age increases. 
Even adopting the most conservative cut-off value for hypovitaminosis D (lower than 50 
nmol/L), it is a frequent condition amongst people aged 65 years or more. In the U.S., the 
prevalence of vitamin D deficiency and vitamin D insufficiency were found to be 28.9% and 41.4%, 
respectively [28] . 
Hypovitaminosis D in older age groups is mainly due to the reduced ability of the skin to 
synthetize cholecalciferol from its precursor: 7-dehydrocholesterol. Together with a reduced 
synthesis of vitamin D, older subjects showed a reduced expression of vitamin D receptors (VDRs). 
These two phenomena cooperate in the amplification of the effect of hypovitaminosis D during 
aging [29] . 
Hypovitaminosis D has been identified as a common feature between diseases widely diffused 
in senescence such as osteoporosis, sarcopenia, and cognitive impairment. 
Although the most well-known clinical effect of hypovitaminosis D is osteoporo-malacia, here 
we will focus on the role of vitamin D in the pathogenesis of sarcopenia and cognitive impairment, 
analyzing studies from experimental models and their clinical relevance. 
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2. Vitamin D and Aging 
2.1. Vitamin D and Muscle Health: From Bench to Bedside 
VDRs are expressed in human muscle fibers, especially during their early developmental 
phases, and decrease upon their maturation [30]. It has been demonstrated in vitro that vitamin D 
plays an active role in muscle maturation as myoblasts can differentiate into myocytes thanks to a 
signal mediated by VDRs [31] . Besides its genomic effects, vitamin D has non-genomic rapid-onset 
effects that can play a role in muscle contraction as it is involved in the regulation of membrane 
calcium channels [32,33]. Vitamin D increases calcium influx in muscle cell cytoplasm within 
minutes in a dose-dependent manner [34,35] through activation of two kinases, namely, c-Src and 
PI3K [36]. PI3K activation leads to an increasing level of inositol triphosphate (IP3) and 
diacylglycerol (DAG); IP3 induces calcium displacement from the sarcoplasm, while DAG, along 
with calcium in the cytosol, is a key component in the activation of protein kinase C (PKC). PKC 
interacts with calcium channels on the cell membrane, leading to more calcium influx in the cytosol 
[37,38]. Calcium binds to the troponin–tropomyosin complex, resulting in the exposure of active 
binding sites, enabling muscle contraction [39]. 
Experimental models of knock-out mice for VDR confirmed this role, as in VDR null mice, the 
muscle mass is reduced and the fibers have a lower diameter in respect to wild-type littermates 
[40]. 
Moreover, muscle development and maturation is impaired in VDR null mice. These mice 
express transcriptional factors typical of early muscle development, such as myf5, E2A, and 
myogenin, for a longer period, suggesting that the VDR is a key player in correct muscle growth 
and maturation [40]. 
The action of vitamin D in muscle development is independent of its effect on blood calcium 
levels, as has been demonstrated in VDR null mice with normal blood calcium [40]. 
Besides the role on muscle development and maturation, a role for vitamin D has also been 
postulated in the control of muscle atrophy. Vitamin D has been implicated in muscular protein 
degradation through the control of the ATP-ubiquitin-dependent system [41]. In rats, a significant 
increase in catalytic activity and in protein ubiquitination during vitamin D deficiency have been 
demonstrated [41] . The increased muscle atrophy associated with vitamin D deficiency is 
associated with reduced anaerobic capacity and tolerance to exercise, together with a disruption of 
muscle morphology demonstrated by low cross-sectional areas of muscle fibers and the reduction 
of fast fibers [42] . 
As VDR expression increases after muscular injury, it has also been suggested that vitamin D 
may have a role in muscle regeneration [32,43]. This could be very important in patients affected by 
sarcopenia who have reduced muscular regeneration. 
Taken together, these experimental data strongly suggest a role for vitamin D in muscle health. 
As regards humans, despite studies’ heterogeneity, a physiological role for vitamin D has been 
envisioned. 
In humans, the role of vitamin D in muscle health is supported by several data: in patients 
with VDR mutations or severe vitamin D deficiency, there is a generalized muscle atrophy and 
muscular sufferance which appears even before the appearance of the altered bone turnover [43]. 
Associated studies have demonstrated that in older age, vitamin D deficiency is strongly linked to 
muscle weakness and loss, suggesting that hypovitaminosis D in the elderly may be an important 
factor in the development of sarcopenia [39,44,45] . In a large study on more than 4000 older 
community-dwelling adults, Aspell et al. showed that patients with vitamin D lower than <30 
nmol/L were more likely to have impaired muscle function with a reduction in physical 
performance and muscle strength, but not an increased risk of falls [46]. 
2.2. Vitamin D Supplements and Muscle Health 
Despite the accumulating evidence on the link between vitamin D deficiency and muscle 
health (especially in older adults), the role of vitamin D supplementation in recovering muscle mass 
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and function is yet to be proven. Meta-analysis and systematic literature reviews were able to find 
only a minor, often non-statistically significant, improvement in muscle strength with vitamin D 
supplementation, even when associated with calcium supplementation and exercise [47,48]. 
A closer look at recent randomized controlled clinical trials, even ones included in the 
aforementioned papers, demonstrates a great deal of heterogeneity in patients, levels of vitamin D 
at baseline, doses of vitamin D supplementation, and even in tests used to measure muscle strength 
and sarcopenia. While it is true that the older population is itself a very heterogeneous group, the 
selection of a more precise section of the population might help in finding results that are more 
suitable to clarify whether vitamin D supplementation has a role in the prevention and treatment of 
age-related muscle loss. 
Moreover, some trials have raised some caveats suggesting that a high bolus of cholecalciferol 
does not prevents falls, but, on the contrary, seems to increase the risk of falling and may be 
ineffective in improving bone mineral density and bone turnover [26]. 
In order to understand these conflicting results, it is important to highlight that the subjects 
included in those papers were not affected by hypovitaminosis D and were treated with doses 
much higher than the ones recommended in clinic [19]. Hence, the conclusions from those papers 
can only be that too much vitamin D, if it is not needed, may be detrimental for unknown reasons. 
Although calcium is important for muscle contraction, randomized clinical trials show no 
additional effect of calcium on muscle strength in young athletes both female [49] and male [50]. 
Furthermore, in older community-dwelling women, the administration of yogurts fortified with 
vitamin D (200 IU) and calcium (400 mg) given twice a day was not able to increase gait 
performance [51]. 
2.3. Vitamin D and Cognitive Health: From Bench to Bedside 
The observation that the VDR is also expressed in the central nervous system (CNS) and that 
CNS is per se able to synthetize calcitriol thanks to the expression of the 25-hydroxylase and 1α-
hydroxylase [52] has raised the hypothesis that vitamin D may have a role in brain health and in 
cognitive performance. 
In a rat model of Alzheimer’s disease (AD), rats fed with low levels of vitamin D lost their 
cognition abilities more rapidly in respect to those fed a control diet [53] . Moreover, in mice with 
low levels of vitamin D, the production of amyloid-β (AB) is increased and there is an increased 
formation of amyloid plaques, as is typically observed in patients affected by AD [54]. In transgenic 
mice who spontaneously accumulate AB and develop AD, a diet supplemented with cholecalciferol 
is able to reduce the amyloid plaque formation by enhancing the amyloid clearance. Consistent 
with histological changes, vitamin D supplements ameliorate animal cognitive performance [55,56]. 
The mechanisms through which vitamin D reduces the accumulation of AB and the formation 
of amyloid plaque are not completely clear. It has been suggested that vitamin D increases the AB 
clearance by the blood–brain barrier, increasing its brain-to-blood efflux though both genomic and 
non-genomic action [57,58]. Moreover, in vitro primary cultures of cortical neurons show that 
vitamin D is directly implicated in the production of Aβ and can downregulate its expression [59]. 
Several genes involved in the pathogenesis of AD have a vitamin D responding element within 
their sequences [60]. These genes are deregulated if vitamin D deficiency occurs during growth 
[61,62]. However, it has never been demonstrated that hypovitaminosis D during growth may 
influence cognitive performance in adult life. 
Despite all the data obtained from in vitro and from animal models, the role of vitamin D in 
cognition is far from being elucidated. Its role is probably complex and mediated through the cross 
talk with other factors such as estrogen and insulin [56]. Transcriptomic analysis of the neocortex of 
healthy mice and those affected by AD showed that after vitamin D treatment there is a 
deregulation of pathways related to inflammation and immune response, neurotransmission, 
vascular processes, and hormonal alterations, suggesting a complex and multiple role for vitamin D 
rather than a single one in the development of dementia [56]. 
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In humans, some studies have suggested that lower levels of vitamin D are associated with 
poorer cognition in patients affected by cognitive problems, however a faster loss of cognitive 
performance has not been demonstrated [63,64] . Furthermore, in older subjects complaining of 
memory deficits without a diagnosis of dementia, hypovitaminosis D has been associated with 
lower cognitive performance, namely, poorer mental flexibility [65]. On the other hand, a recent 
study performed with the Mendelian randomization method found no evidence that 
hypovitaminosis D may be a cause of cognitive deficits in mid- or later life [66]. 
Due to the high heterogeneity of the methods used and of the population analyzed, it is 
difficult to find homogeneous results. Nevertheless, a recent meta-analysis including both patients 
with impaired cognition and healthy subjects suggests that poorer vitamin D status is associated 
with poorer cognitive performance with respect to high vitamin D levels, however, the author 
acknowledges possible publication biases [67]. 
Data obtained in animals and associated studies in humans have brought substantial attention 
to the possible role of vitamin D supplements in preventing cognitive decline in humans. However, 
the data obtained in different studies are difficult to interpret and do not clearly highlight the role 
of vitamin D in the pathogenesis and treatment of dementia. Interventional studies are less 
common than observational ones, and results are more inconclusive because the protocols used for 
supplementation and the population included are largely different. The durations of treatment vary 
from a single dose to 18 weeks, with different dosages and different molecules. Dhesi and 
colleagues [68] used ergocalciferol as a single intramuscular injection of 600,000 IU, Przybelski and 
colleagues used oral ergocalciferol of 50,000 IU three times a week for four weeks [69], Dean and 
colleagues used oral cholecalciferol capsules of 5000 IU daily [70], whereas Pettersen used oral 
cholecalciferol in two different doses of 4000 IU versus 400 IU daily for 18 weeks [71]. Moreover, the 
population enrolled was different with regards to age: old subjects [72] versus young [47]. The 
settings are also different: community-dwelling residents versus nursing home residents [73,74] . 
The vitamin D status at inclusion in the study is also different: in the study by Dhesi and colleagues 
[68], the subjects included were vitamin D deficient, while in the others they could be deficient or 
not [69,70]. In addition, the study designs are different, as two studies used a placebo-controlled 
group [68,70] and others did not [69,71]. 
Recent meta-analyses reviewed three of the four interventional studies cited [68,70] and found 
that 314 subjects saw no significant benefit in patients treated with vitamin D supplementation [67] . 
On the other hand, the study by Pettersen suggested an effect of high doses of cholecalciferol (4000 
IU/d) in the amelioration of visual memory in heathy adults, particularly among those who had low 
levels of vitamin D at their enrolment in the trial. 
As regards the supplementation of vitamin D together with calcium, a recent randomized 
controlled clinical trial in healthy older females showed that yogurts fortified with low doses of 
vitamin D (200 IU) and calcium (400 mg) given twice a day helped in the maintenance of cognitive 
performance [51]. 
Taken together, these data suggest that although vitamin D may have a role in the 
development of the brain and in cognition, data obtained by intervention studies are not sufficient 
to indicate that the administration of vitamin D, even at high doses, may be useful for patients with 
impaired cognition. Data on the use of calcium supplements associated with vitamin D are not 
sufficient to recommend the double supplementation, and further studies are needed to clarify 
these indications. 
3. Conclusions 
Progressive increases in life expectancy are associated with a constant increase of chronic 
diseases associated with age that have a great impact on patients’ quality of life and consistently 
increase sanitary costs as well as the risks of sarcopenia and dementia. 
Hypovitaminosis D is associated with aging and with these chronic diseases. Even though a 
clear pathogenic mechanism is still not elucidated, association studies have shown a relationship 
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between low vitamin D levels and sarcopenia and dementia. However, interventional studies are 
not sufficient to recommend treatment with vitamin D to efficiently treat these two diseases. 
Author Contributions: Conceptualization P.D., bibliographic research P.D. and L.Q.; writing—review and 
editing, P.D. and L.Q. All authors have read and agreed to the published version of the manuscript. 
Funding: This research received no external funding. 
Acknowledgements: The authors thank Francesco Cattaneo for drawing the old man used in the graphical 
abstract. 
Conflicts of Interest: The authors declare no conflicts of interest. 
References 
1. Fried, L.P.; Tangen, C.M.; Walston, J.; Newman, A.B.; Hirsch, C.; Gottdiener, J.; Seeman, T.; Tracy, R.; Kop, 
W.J.; Burke, G.; et al. Frailty in older adults: evidence for a phenotype. J. Gerontol. A Biol. Sci. Med. Sci. 
2001, 56, M146–M156. 
2. Ruan, Q.; Yu, Z.; Chen, M.; Bao, Z.; Li, J.; He, W. Cognitive frailty, a novel target for the prevention of 
elderly dependency. Ageing Res. Rev. 2015, 20, 1–10. 
3. Dodds, R.M.; Roberts, H.C.; Cooper, C.; Sayer, A.A. The Epidemiology of Sarcopenia. J. Clin. Densitom. 
2015, 18, 461–466. 
4. Cruz-Jentoft, A.J.; Bahat, G.; Bauer, J.; Boirie, Y.; Bruyère, O.; Cederholm, T.; Cooper, C.; Landi, F.; Rolland, 
Y.; Sayer, A.A.; et al. Sarcopenia: revised European consensus on definition and diagnosis. Age Ageing 
2019, 48, 16–31. 
5. Mayhew, A.J.; Amog, K.; Phillips, S.; Parise, G.; McNicholas, P.D.; de Souza, R.J.; Thabane, L.; Raina, P. 
The prevalence of sarcopenia in community-dwelling older adults, an exploration of differences between 
studies and within definitions: a systematic review and meta-analyses. Age Ageing 2019, 48, 48–56. 
6. Shafiee, G.; Keshtkar, A.; Soltani, A.; Ahadi, Z.; Larijani, B.; Heshmat, R. Prevalence of sarcopenia in the 
world: a systematic review and meta- analysis of general population studies. J. Diabetes Metab. Disord. 
2017, 16, 21. 
7. Chumlea, WM.C.; Cesari, M.; Evans, W.J.; Ferrucci, L.; Fielding, R.A.; Pahor, M.; Studenski, S.; Vellas, B.; 
The Task Force Members International working group on Sarcopenia. J. Nutr. Health Aging 2011, 15, 450–
455. 
8. Cruz-Jentoft, A.J.; Baeyens, J.P.; Bauer, J.M.; Boirie, Y.; Cederholm, T.; Landi, F.; Martin, F.C.; Michel, J.-P.; 
Rolland, Y.; Schneider, S.M.; et al. Sarcopenia: European consensus on definition and diagnosis Report of 
the European Working Group on Sarcopenia in Older People. Age Ageing 2010, 39, 412–423. 
9. Studenski, S.A.; Peters, K.W.; Alley, D.E.; Cawthon, P.M.; McLean, R.R.; Harris, T.B.; Ferrucci, L.; 
Guralnik, J.M.; Fragala, M.S.; Kenny, A.M.; et al. The FNIH sarcopenia project: rationale, study 
description, conference recommendations, and final estimates. J. Gerontol. A Biol. Sci. Med. Sci. 2014, 69, 
547–558. 
10. Baumgartner, R.N.; Koehler, K.M.; Gallagher, D.; Romero, L.; Heymsfield, S.B.; Ross, R.R.; Garry, P.J.; 
Lindeman, R.D. Epidemiology of sarcopenia among the elderly in New Mexico. Am. J. Epidemiol. 1998, 147, 
755–763. 
11. Newman, A.B.; Kupelian, V.; Visser, M.; Simonsick, E.; Goodpaster, B.; Nevitt, M.; Kritchevsky, S.B.; 
Tylavsky, F.A.; Rubin, S.M.; Harris, T.B.; et al. Sarcopenia: alternative definitions and associations with 
lower extremity function. J. Am. Geriatr. Soc. 2003, 51, 1602–1609. 
12. Marty, E.; Liu, Y.; Samuel, A.; Or, O.; Lane, J. A review of sarcopenia: Enhancing awareness of an 
increasingly prevalent disease. Bone 2017, 105, 276–286. 
13. Sousa, A.S.; Guerra, R.S.; Fonseca, I.; Pichel, F.; Ferreira, S.; Amaral, T.F. Financial impact of sarcopenia on 
hospitalization costs. Eur. J. Clin. Nutr. 2016, 70, 1046–1051. 
14. World Alzheimer Report 2018: The state of the art of dementia research: New frontiers | Alzheimer’s 
Disease International Available online: https://www.alz.co.uk/news/world-alzheimer-report-2018-state-of-
art-of-dementia-research-new-frontiers (accessed on 28 January 2020). 
15. Wimo, A.; Guerchet, M.; Ali, G.-C.; Wu, Y.-T.; Prina, A.M.; Winblad, B.; Jönsson, L.; Liu, Z.; Prince, M. The 
worldwide costs of dementia 2015 and comparisons with 2010. Alzheimers Dement. 2017, 13, 1–7. 
Nutrients 2020, 12, 628 8 of 11 
16. Institute of Medicine (US) Committee to Review Dietary Reference Intakes for Vitamin D and Calcium 
Dietary Reference Intakes for Calcium and Vitamin D.; Ross, A.C., Taylor, C.L., Yaktine, A.L., Del Valle, H.B., 
Eds.; The National Academies Collection: Reports funded by National Institutes of Health; National 
Academies Press (US): Washington, DC, USA, 2011. 
17. Ross, A.C.; Manson, J.E.; Abrams, S.A.; Aloia, J.F.; Brannon, P.M.; Clinton, S.K.; Durazo-Arvizu, R.A.; 
Gallagher, J.C.; Gallo, R.L.; Jones, G.; et al. The 2011 report on dietary reference intakes for calcium and 
vitamin D from the Institute of Medicine: what clinicians need to know. J. Clin. Endocrinol. Metab. 2011, 96, 
53–58. 
18. Rossini, M.; Adami, S.; Bertoldo, F.; Diacinti, D.; Gatti, D.; Giannini, S.; Giusti, A.; Malavolta, N.; Minisola, 
S.; Osella, G.; et al. Guidelines for the diagnosis, prevention and management of osteoporosis. Reumatismo 
2016, 68, 1–39. 
19. Cesareo, R.; Attanasio, R.; Caputo, M.; Castello, R.; Chiodini, I.; Falchetti, A.; Guglielmi, R.; Papini, E.; 
Santonati, A.; Scillitani, A.; et al. Italian Association of Clinical Endocrinologists (AME) and Italian 
Chapter of the American Association of Clinical Endocrinologists (AACE) Position Statement: Clinical 
Management of Vitamin D Deficiency in Adults. Nutrients 2018, 10, 546. 
20. Valcour, A.; Blocki, F.; Hawkins, D.M.; Rao, S.D. Effects of age and serum 25-OH-vitamin D on serum 
parathyroid hormone levels. J. Clin. Endocrinol. Metab. 2012, 97, 3989–3995. 
21. Bhattoa, H.P.; Konstantynowicz, J.; Laszcz, N.; Wojcik, M.; Pludowski, P. Vitamin D: Musculoskeletal 
health. Rev. Endocr. Metab. Disord. 2017, 18, 363–371. 
22. Priemel, M.; von Domarus, C.; Klatte, T.O.; Kessler, S.; Schlie, J.; Meier, S.; Proksch, N.; Pastor, F.; Netter, 
C.; Streichert, T.; et al. Bone mineralization defects and vitamin D deficiency: histomorphometric analysis 
of iliac crest bone biopsies and circulating 25-hydroxyvitamin D in 675 patients. J. Bone Miner. Res. 2010, 
25, 305–312. 
23. Reid, I.R.; Horne, A.M.; Mihov, B.; Gamble, G.D.; Al-Abuwsi, F.; Singh, M.; Taylor, L.; Fenwick, S.; 
Camargo, C.A.; Stewart, A.W.; et al. Effect of monthly high-dose vitamin D on bone density in 
community-dwelling older adults substudy of a randomized controlled trial. J. Intern. Med. 2017, 282, 452–
460. 
24. Macdonald, H.M.; Reid, I.R.; Gamble, G.D.; Fraser, W.D.; Tang, J.C.; Wood, A.D. 25-Hydroxyvitamin D 
Threshold for the Effects of Vitamin D Supplements on Bone Density: Secondary Analysis of a 
Randomized Controlled Trial. J. Bone Miner. Res. 2018, 33, 1464–1469. 
25. Sanders, K.M.; Stuart, A.L.; Williamson, E.J.; Simpson, J.A.; Kotowicz, M.A.; Young, D.; Nicholson, G.C. 
Annual high-dose oral vitamin D and falls and fractures in older women: a randomized controlled trial. 
JAMA 2010, 303, 1815–1822. 
26. Bischoff-Ferrari, H.A.; Dawson-Hughes, B.; Orav, E.J.; Staehelin, H.B.; Meyer, O.W.; Theiler, R.; Dick, W.; 
Willett, W.C.; Egli, A. Monthly High-Dose Vitamin D Treatment for the Prevention of Functional Decline: 
A Randomized Clinical Trial. JAMA Intern. Med. 2016, 176, 175–183. 
27. Amrein, K.; Quraishi, S.A.; Litonjua, A.A.; Gibbons, F.K.; Pieber, T.R.; Camargo, C.A.; Giovannucci, E.; 
Christopher, K.B. Evidence for a U-shaped relationship between prehospital vitamin D status and 
mortality: a cohort study. J. Clin. Endocrinol. Metab. 2014, 99, 1461–1469. 
28. Liu, X.; Baylin, A.; Levy, P.D. Vitamin D deficiency and insufficiency among US adults: prevalence, 
predictors and clinical implications. Br. J. Nutr. 2018, 119, 928–936. 
29. Scimeca, M.; Centofanti, F.; Celi, M.; Gasbarra, E.; Novelli, G.; Botta, A.; Tarantino, U. Vitamin D Receptor 
in Muscle Atrophy of Elderly Patients: A Key Element of Osteoporosis-Sarcopenia Connection. Aging Dis 
2018, 9, 952–964. 
30. Bischoff, H.A.; Borchers, M.; Gudat, F.; Duermueller, U.; Theiler, R.; Stähelin, H.B.; Dick, W. In situ 
detection of 1,25-dihydroxyvitamin D3 receptor in human skeletal muscle tissue. Histochem. J. 2001, 33, 19–
24. 
31. Tanaka, M.; Kishimoto, K.N.; Okuno, H.; Saito, H.; Itoi, E. Vitamin D receptor gene silencing effects on 
differentiation of myogenic cell lines. Muscle Nerve 2014, 49, 700–708. 
32. Srikuea, R.; Zhang, X.; Park-Sarge, O.-K.; Esser, K.A. VDR and CYP27B1 are expressed in C2C12 cells and 
regenerating skeletal muscle: potential role in suppression of myoblast proliferation. Am. J. Physiol., Cell 
Physiol. 2012, 303, C396–C405. 
33. Floyd, M.; Ayyar, D.R.; Barwick, D.D.; Hudgson, P.; Weightman, D. Myopathy in chronic renal failure. Q. 
J. Med. 1974, 43, 509–524. 
Nutrients 2020, 12, 628 9 of 11 
34. de Boland, A.R.; Massheimer, V.; Fernandez, L.M. 1,25 Dihydroxyvitamin D3 affects calmodulin 
distribution among subcellular fractions of skeletal muscle. Calcif. Tissue Int. 1988, 43, 370–375. 
35. Santillán, G.; Katz, S.; Vazquez, G.; Boland, R.L. TRPC3-like protein and vitamin D receptor mediate 
1alpha,25(OH)2D3-induced SOC influx in muscle cells. Int. J. Biochem. Cell Biol. 2004, 36, 1910–1918. 
36. Buitrago, C.; Vazquez, G.; De Boland, A.R.; Boland, R.L. Activation of Src kinase in skeletal muscle cells by 
1, 1,25-(OH(2))-vitamin D(3) correlates with tyrosine phosphorylation of the vitamin D receptor (VDR) 
and VDR-Src interaction. J. Cell. Biochem. 2000, 79, 274–281. 
37. Morelli, S.; de Boland, A.R.; Boland, R.L. Generation of inositol phosphates, diacylglycerol and calcium 
fluxes in myoblasts treated with 1,25-dihydroxyvitamin D3. Biochem. J. 1993, 289 ( Pt 3), 675–679. 
38. Buitrago, C.; González Pardo, V.; de Boland, A.R. Nongenomic action of 1 alpha,25(OH)(2)-vitamin D3. 
Activation of muscle cell PLC gamma through the tyrosine kinase c-Src and PtdIns 3-kinase. Eur. J. 
Biochem. 2002, 269, 2506–2515. 
39. Berchtold, M.W.; Brinkmeier, H.; Müntener, M. Calcium ion in skeletal muscle: its crucial role for muscle 
function, plasticity, and disease. Physiol. Rev. 2000, 80, 1215–1265. 
40. Endo, I.; Inoue, D.; Mitsui, T.; Umaki, Y.; Akaike, M.; Yoshizawa, T.; Kato, S.; Matsumoto, T. Deletion of 
vitamin D receptor gene in mice results in abnormal skeletal muscle development with deregulated 
expression of myoregulatory transcription factors. Endocrinology 2003, 144, 5138–5144. 
41. Bhat, M.; Kalam, R.; Qadri, S.S.; Madabushi, S.; Ismail, A. Vitamin D deficiency-induced muscle wasting 
occurs through the ubiquitin proteasome pathway and is partially corrected by calcium in male rats. 
Endocrinology 2013, 154, 4018–4029. 
42. Sleeman, I.; Aspray, T.; Lawson, R.; Coleman, S.; Duncan, G.; Khoo, T.K.; Schoenmakers, I.; Rochester, L.; 
Burn, D.; Yarnall, A. The Role of Vitamin D in Disease Progression in Early Parkinson’s Disease. J. 
Parkinsons Dis. 2017, 7, 669–675. 
43. Girgis, C.M.; Clifton-Bligh, R.J.; Turner, N.; Lau, S.L.; Gunton, J.E. Effects of vitamin D in skeletal muscle: 
falls, strength, athletic performance and insulin sensitivity. Clin. Endocrinol. (Oxf) 2014, 80, 169–181. 
44. Lappe, J.M.; Binkley, N. Vitamin D and Sarcopenia/Falls. J. Clin. Densit. 2015, 18, 478–482. 
45. Verde, Z.; Giaquinta, A.; Sainz, C.M.; Ondina, M.D.; Araque, A.F. Bone Mineral Metabolism Status, 
Quality of Life, and Muscle Strength in Older People. Nutrients 2019, 11, 2748. 
46. Aspell, N.; Laird, E.; Healy, M.; Lawlor, B.; O’Sullivan, M. Vitamin D Deficiency Is Associated With 
Impaired Muscle Strength And Physical Performance In Community-Dwelling Older Adults: Findings 
From The English Longitudinal Study Of Ageing. Clin. Interv. Aging 2019, 14, 1751–1761. 
47. Agergaard, J.; Trøstrup, J.; Uth, J.; Iversen, J.V.; Boesen, A.; Andersen, J.L.; Schjerling, P.; Langberg, H. 
Does vitamin-D intake during resistance training improve the skeletal muscle hypertrophic and strength 
response in young and elderly men? - a randomized controlled trial. Nutr. Metab. (Lond) 2015, 12, 32. 
48. Tabrizi, R.; Hallajzadeh, J.; Mirhosseini, N.; Lankarani, K.B.; Maharlouei, N.; Akbari, M.; Asemi, Z. The 
effects of vitamin D supplementation on muscle function among postmenopausal women: a systematic 
review and meta-analysis of randomized controlled trials. EXCLI J 2019, 18, 591–603. 
49. Goswami, R.; Vatsa, M.; Sreenivas, V.; Singh, U.; Gupta, N.; Lakshmy, R.; Aggarwal, S.; Ganapathy, A.; 
Joshi, P.; Bhatia, H. Skeletal muscle strength in young Asian Indian females after vitamin D and calcium 
supplementation: a double-blind randomized controlled clinical trial. J. Clin. Endocrinol. Metab. 2012, 97, 
4709–4716. 
50. Saha, S.; Goswami, R.; Ramakrishnan, L.; Vishnubhatla, S.; Mahtab, S.; Kar, P.; Srinivasan, S.; Singh, N.; 
Singh, U. Vitamin D and calcium supplementation, skeletal muscle strength and serum testosterone in 
young healthy adult males: Randomized control trial. Clin. Endocrinol. (Oxf) 2018, 88, 217–226. 
51. Beauchet, O.; Launay, C.P.; Galery, K.; Vilcocq, C.; Dontot-Payen, F.; Rousseau, B.; Benoit, V.; Allali, G. 
Effects of Vitamin D and Calcium Fortified Yogurts on Gait, Cognitive Performances, and Serum 25-
Hydroxyvitamin D Concentrations in Older Community-Dwelling Females: Results from the GAit, 
MEmory, Dietary and Vitamin D (GAME-D2) Randomized Controlled Trial. Nutrients 2019, 11, 2880. 
52. Garcion, E.; Wion-Barbot, N.; Montero-Menei, C.N.; Berger, F.; Wion, D. New clues about vitamin D 
functions in the nervous system. Trends Endocrinol. Metab. 2002, 13, 100–105. 
53. Taghizadeh, M.; Djazayery, A.; Salami, M.; Eshraghian, M.R.; Zavareh, S.A.T. Vitamin-D-free regimen 
intensifies the spatial learning deficit in Alzheimer’s disease. Int. J. Neurosci. 2011, 121, 16–24. 
Nutrients 2020, 12, 628 10 of 11 
54. Grimm, M.O.W.; Lehmann, J.; Mett, J.; Zimmer, V.C.; Grösgen, S.; Stahlmann, C.P.; Hundsdörfer, B.; 
Haupenthal, V.J.; Rothhaar, T.L.; Herr, C.; et al. Impact of Vitamin D on amyloid precursor protein 
processing and amyloid-β peptide degradation in Alzheimer’s disease. Neurodegener. Dis. 2014, 13, 75–81. 
55. Yu, J.; Gattoni-Celli, M.; Zhu, H.; Bhat, N.R.; Sambamurti, K.; Gattoni-Celli, S.; Kindy, M.S. Vitamin D3-
enriched diet correlates with a decrease of amyloid plaques in the brain of AβPP transgenic mice. J. 
Alzheimers Dis. 2011, 25, 295–307. 
56. Landel, V.; Millet, P.; Baranger, K.; Loriod, B.; Féron, F. Vitamin D interacts with Esr1 and Igf1 to regulate 
molecular pathways relevant to Alzheimer’s disease. Mol. Neurodegener. 2016, 11, 22. 
57. Ito, S.; Ohtsuki, S.; Nezu, Y.; Koitabashi, Y.; Murata, S.; Terasaki, T. 1α,25-Dihydroxyvitamin D3 enhances 
cerebral clearance of human amyloid-β peptide(1-40) from mouse brain across the blood-brain barrier. 
Fluids Barriers CNS 2011, 8, 20. 
58. Guo, Y.-X.; He, L.-Y.; Zhang, M.; Wang, F.; Liu, F.; Peng, W.-X. 1,25-Dihydroxyvitamin D3 regulates 
expression of LRP1 and RAGE in vitro and in vivo, enhancing Aβ1-40 brain-to-blood efflux and peripheral 
uptake transport. Neuroscience 2016, 322, 28–38. 
59. Gezen-Ak, D.; Atasoy, I.L.; Candaş, E.; Alaylioglu, M.; Yılmazer, S.; Dursun, E. Vitamin D Receptor 
Regulates Amyloid Beta 1-42 Production with Protein Disulfide Isomerase A3. ACS Chem. Neurosci. 2017, 
8, 2335–2346. 
60. DeLuca, G.C.; Kimball, S.M.; Kolasinski, J.; Ramagopalan, S.V.; Ebers, G.C. Review: the role of vitamin D 
in nervous system health and disease. Neuropathol. Appl. Neurobiol. 2013, 39, 458–484. 
61. Almeras, L.; Eyles, D.; Benech, P.; Laffite, D.; Villard, C.; Patatian, A.; Boucraut, J.; Mackay-Sim, A.; 
McGrath, J.; Féron, F. Developmental vitamin D deficiency alters brain protein expression in the adult rat: 
implications for neuropsychiatric disorders. Proteomics 2007, 7, 769–780. 
62. Eyles, D.; Almeras, L.; Benech, P.; Patatian, A.; Mackay-Sim, A.; McGrath, J.; Féron, F. Developmental 
vitamin D deficiency alters the expression of genes encoding mitochondrial, cytoskeletal and synaptic 
proteins in the adult rat brain. J. Steroid Biochem. Mol. Biol. 2007, 103, 538–545. 
63. van Schoor, N.M.; Comijs, H.C.; Llewellyn, D.J.; Lips, P. Cross-sectional and longitudinal associations 
between serum 25-hydroxyvitamin D and cognitive functioning. Int. Psychogeriatr. 2016, 28, 759–768. 
64. Gschwind, Y.J.; Bischoff-Ferrari, H.A.; Bridenbaugh, S.A.; Härdi, I.; Kressig, R.W. Association between 
serum vitamin D status and functional mobility in memory clinic patients aged 65 years and older. 
Gerontology 2014, 60, 123–129. 
65. Annweiler, C.; Maby, E.; Meyerber, M.; Beauchet, O. Hypovitaminosis D and executive dysfunction in 
older adults with memory complaint: a memory clinic-based study. Dement. Geriatr. Cogn. Disord. 2014, 37, 
286–293. 
66. Maddock, J.; Zhou, A.; Cavadino, A.; Kuźma, E.; Bao, Y.; Smart, M.C.; Saum, K.-U.; Schöttker, B.; 
Engmann, J.; Kjærgaard, M.; et al. Vitamin D and cognitive function: A Mendelian randomisation study. 
Sci. Rep. 2017, 7, 13230. 
67. Goodwill, A.M.; Szoeke, C. A Systematic Review and Meta-Analysis of The Effect of Low Vitamin D on 
Cognition. J. Am. Geriatr. Soc. 2017, 65, 2161–2168. 
68. Dhesi, J.K.; Jackson, S.H.D.; Bearne, L.M.; Moniz, C.; Hurley, M.V.; Swift, C.G.; Allain, T.J. Vitamin D 
supplementation improves neuromuscular function in older people who fall. Age Ageing 2004, 33, 589–595. 
69. Przybelski, R.; Agrawal, S.; Krueger, D.; Engelke, J.A.; Walbrun, F.; Binkley, N. Rapid correction of low 
vitamin D status in nursing home residents. Osteoporos Int. 2008, 19, 1621–1628. 
70. Dean, A.J.; Bellgrove, M.A.; Hall, T.; Phan, W.M.J.; Eyles, D.W.; Kvaskoff, D.; McGrath, J.J. Effects of 
vitamin D supplementation on cognitive and emotional functioning in young adults--a randomised 
controlled trial. PLoS ONE 2011, 6, e25966. 
71. Pettersen, J.A. Does high dose vitamin D supplementation enhance cognition?: A randomized trial in 
healthy adults. Exp. Gerontol. 2017, 90, 90–97. 
72. Rosendahl-Riise, H.; Spielau, U.; Ranhoff, A.H.; Gudbrandsen, O.A.; Dierkes, J. Vitamin D 
supplementation and its influence on muscle strength and mobility in community-dwelling older persons: 
a systematic review and meta-analysis. J. Hum. Nutr. Diet 2017, 30, 3–15. 
73. Smedshaug, G.B.; Pedersen, J.I.; Meyer, H.E. Can vitamin D supplementation improve grip strength in 
elderly nursing home residents? A double-blinded controlled trial. Scand. J. Food Nutr. 2007, 51, 74–78. 
Nutrients 2020, 12, 628 11 of 11 
74. Moreira-Pfrimer, L.D.F.; Pedrosa, M.A.C.; Teixeira, L.; Lazaretti-Castro, M. Treatment of vitamin D 
deficiency increases lower limb muscle strength in institutionalized older people independently of regular 
physical activity: a randomized double-blind controlled trial. Ann. Nutr. Metab. 2009, 54, 291–300. 
 
© 2020 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open 
access article distributed under the terms and conditions of the Creative Commons 
Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/). 
 
